Epilepsy is a chronic neurological disorder that affects approximately 1% of
the global population, including 1 in 200 children. Managing pediatric epilepsy
often relies on anticonvulsant monotherapy, but the optimal drug choice remains
a topic of debate. Levetiracetam (LEV) and carbamazepine (CBZ) are both common
treatments, each with specific benefits and distinct side effect profiles.
This study analyzed the efficacy and safety of LEV and CBZ in children and
adolescents with focal epilepsy, aiming to provide clearer therapeutic
guidance.
Levetiracetam: A
More Advantageous Option in Epileptic Children?
This study pooled data from four randomized controlled trials, including 381
patients, using robust statistical models to evaluate the effects of each
treatment. Key outcome measures include seizure freedom and frequency, adverse
event frequency (all types and those leading to treatment discontinuation), and
incidence of dermatological adverse events.
Findings indicate that:
- Both treatments showed similar efficacy in
achieving seizure freedom and total seizure prevention.
- LEV demonstrated a significantly lower
frequency of seizures and dermatological adverse events compared to CBZ.
- No significant difference was observed in
the overall rate of adverse events or events leading to treatment
discontinuation.
Levetiracetam as a
Promising Therapy in Pediatric Epilepsy
The results position LEV as a promising option for monotherapy in pediatric
focal epilepsy, especially for children sensitive to dermatological side
effects or requiring a reduction in seizure frequency. However, further
research is needed to deepen the understanding of the efficacy and safety of
these antiepileptic medications in children and adolescents and to refine
recommendations for this population.
